Morocco Pharmaceuticals and Healthcare Report Q1 2013


January 16, 2013
101 Pages - SKU: BMI4943996
License type:
Countries covered: Morocco

BMI View: Morocco's subsidised health insurance scheme, Régime d'Assistance Médicale(RAMED), launched in March 2012, is experiencing early-stage difficulties with its target toincrease healthcare accessibility to those on low incomes. This is to be expected, given the evidence ofbribery and corruption, and the shortage of doctors in the sector. BMI believes the commitment toimprove governance and implement controls in the sector will be fulfilled in the medium-to-long term. Assuch, we maintain that government healthcare spending will outpace private healthcare spending overthe forecast 2011-2016 period.

Headline Expenditure Projections

Pharmaceuticals: MAD10.10bn (US$1.25bn) in 2011 to MAD11.24bn (US$1.30bn) in 2012;+11.3% in local currency terms and +4.5% in US dollar terms. Forecast broadly unchangedfrom Q412.

Healthcare: MAD41.99bn (US$5.19bn) in 2011 to MAD47.09bn (US$5.46bn) in 2012; +12.2%in local currency terms and +5.4% in US dollar terms. Forecast slightly higher from Q412, onaccount of slightly lower historical figures.

Medical devices: MAD2.19bn (US$270mn) in 2011 to MAD2.47bn (US$287mn) in 2012;+13.1% in local currency terms and +6.2% in US dollar terms. Forecast broadly unchangedfrom Q412.

Risk/Reward Rating: In Q113, Morocco remains 12th out of the 30 markets included in the MEAregion. Its composite score remains unchanged, at 46.8 out of the maximum 100. The country's rewardsratings are less promising than its risks profile, which weighs down its overall score. The market ismedium-sized by regional standards and small on a global scale, but its high growth potential offsetsrelatively low per capita drug consumption, especially in rural areas. In the risks category, Moroccoscores above the regional average, indicating a relatively low level of country and pharmaceuticalindustry-specific risk in a somewhat volatile region.

Key Trends And Developments

Emergency and psychiatric care will hold a top priority in the country's health reform, saidMorocco's Health Minister Houcine El Ouardi to local press in November 2012. The ministerwill address the acute shortage of psychiatrists and specialist nurses in Morocco. El Ouardiassured that the ministry is working towards the development of a community-based policy onhospital and pre-hospital emergency care. The health ministry will establish four universitydepartments specialising in child and adolescent psychiatry, where ten psychiatrists can betrained every year.

In October 2012, United Arab Emirates (UAE)-based developer Tasweek Real EstateDevelopment and Marketing was reported to be planning to build a healthcare city inMarrakesh, Morocco, according to CEO Masood al-Awar. Tasweek has already gainedapprovals for Marrakesh Healthcare City and all the components required for its constructionhave arrived, Awar told Arabian Business. The US$40mn healthcare city will cover an area ofnearly 21,000m2 and will feature a 40-room boutique hotel, a 160-bed private hospital and 56residential apartments. Tasweek will start construction work in 3-6 months, with the workexpected to be complete by 2014.

BMI Economic View: Despite not possessing hydrocarbon wealth, the economy will remain a relativeoutperformer in North Africa over the medium term. Though we expect 2013 to be a challenging year asexposure to the European recession takes its toll, investor interest in the country as an export-orientedmanufacturing hub for the European market, coupled with a burgeoning tourism industry, should bodewell for Morocco's underlying growth momentum through to 2015. Our forecasts for both economicactivity and fiscal policy assume that Morocco will benefit from significant inflows of foreign aid fromthe Gulf Co-operation Council (GCC) and other organisations in 2012 and 2013. Should this assistancefail to materialise, it would pose serious downside risks to the country's outlook.

BMI Political View: Given the deteriorating state of the Moroccan economy and stagnating politicalliberalisation, popular support for the Benkirane administration is likely to evaporate further in thecoming quarters. With the monarchy continuing to assert its control over the government, a return of theprotest movement that started in 2011 cannot be ruled out. A ministerial reshuffling is also looking likely,potentially introducing instability at the top of the policy ladder.


Executive Summary
SWOT Analysis
Morocco Pharmaceuticals And Healthcare Industry SWOT
Morocco Political SWOT
Morocco Economic SWOT
Morocco Business Environment SWOT
Pharmaceutical Risk/Reward Ratings
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q113
Rewards
Risks
Market Summary - Morocco
Regulatory Regime
Intellectual Property Regime
Pricing Regime
Reimbursement Regime
Table: National Insurance Fund Spending On Select Conditions, 2006-2009
Industry Developments
Epidemiology
Communicable Diseases
Non-Communicable Diseases
Healthcare Sector
Healthcare Financing
Healthcare Sector Developments
Healthcare Reform
Health Insurance
Recent Health Insurance Developments
Clinical Trials
Research & Development
Medical Devices Market
Industry Forecast Scenario
Pharmaceutical Market Forecasts
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors - Macroeconomic Forecast
Table: Morocco - Economic Activity
Prescription Drug Market Forecast
Table: Leading Therapeutic Classes, 2010
Table: Private Pharmacy Sales Value And Volume By Principal Therapeutic Categories, 2010
Table: Prescription Drug Sales Indicators, 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators, 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators, 2008-2016
Pharmaceuticals Trade Forecast
Table: Exports And Imports Indicators, 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators, 2008-2016
Other Healthcare Data Forecasts
Key Risks To BMI's Forecasts
Competitive Landscape
Pharmaceutical Industry
Table: Members Of AMIP, 2011
Table: Members Of MIS, 2011
Domestic Pharmaceutical Sector
Foreign Pharmaceutical Companies
Pharmaceutical Wholesale
Pharmaceutical Retail
Company Profiles
Local Companies
Sothema
Laprophan
Promopharm
Multinational Companies
Sanofi
Pfizer
GlaxoSmithKline
Ranbaxy
Table: Morocco's Population By Age Group, 1990-2020 ('000)
Table: Morocco's Population By Age Group, 1990-2020 (% of total)
Table: Morocco's Key Population Ratios, 1990-2020
Table: Morocco's Rural And Urban Population, 1990-2020
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

More Prescription Drugs reports by Business Monitor International

Ukraine Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Foreign and domestic drugmakers in Ukraine will see their operating margins squeezedfrom 2013 as the Ministry of Health introduces more severe limits on ...
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Sudan and South Sudan's will continue to be of least interest to foreign pharmaceutical firmsin the Middle East and North Africa region as ...
Portugal Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Portugal's pharmaceutical and healthcare sector has been transformed since the interventionof the EU, IMF and ECB as part of the country's EUR78bn economic ...
Poland Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: The Polish pharmaceutical market contracted severely in 2012, owing to harsh pricingmeasures and strict margins imposed on wholesalers, pharmaceutical makers and retailers. Moreover,over ...
See all reports like this >>

More Morocco Prescription Drugs reports

Morocco Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: Morocco’s pharmaceutical market is medium-sized by regional standards and small on aglobal scale, but its high growth potential offers some attraction which its ...
Antibiotics Market in Morocco to 2016 by Global Research & Data Services
This market research report offers a perspective on the actual market situation, trends and future outlook for antibiotics in Morocco. The study provides essential market ...
The Pharmaceutical Market: Morocco by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
Morocco Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Morocco’s pharmaceutical and healthcare market developments this year will be shaped by the delayed rollout of the national health insurance scheme. On the ...
See all reports like this >>

More Morocco reports

D&B Country RiskLine Report: Morocco by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: Morocco by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Morocco: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on Morocco, providing an overview of its political, economic and business environment, represented both textually and in graph and ...
See all reports like this >>